Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2014.02.008
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Late Hematological Improvement of Myelodysplastic Syndrome Following Treatment With 5-Azacitidine Therapy

Internal Medicine
Internal MedicineMedicine
2014English

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Biology of Blood and Marrow Transplantation
TransplantationHematology
2012English

Azacitidine-Induced Pyoderma Gangrenosum at Injection Sites in a Patient With Myelodysplastic Syndrome

Journal of the American Academy of Dermatology
Dermatology
2017English

Image Gallery: Pyoderma Gangrenosum in a Patient With Myelodysplastic Syndrome Treated With Azacitidine

British Journal of Dermatology
DermatologyMedicine
2017English

Safety and Efficacy of Azacitidine in the Treatment of Elderly Patients With Myelodysplastic Syndrome

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2012English

Cost-Effectiveness in Canada of Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndromes

Current Oncology
Oncology
2013English

A 5-Day Regimen of Azacitidine for Lower-Risk Myelodysplastic Syndromes (RA or RARS): A Prospective Single-Arm Phase 2 Trial

Cancer Science
Cancer ResearchMedicineOncology
2018English

Sequential Allogeneic Stem Cell Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

A Case of Myelodysplastic Syndrome With Intestinal Behçet’s Disease-Like Symptoms Treated by Prednisolone and Azacitidine

American Journal of Case Reports
Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy